Search

Your search keyword '"Craxi A."' showing total 182 results

Search Constraints

Start Over You searched for: Author "Craxi A." Remove constraint Author: "Craxi A." Topic hepatology Remove constraint Topic: hepatology
182 results on '"Craxi A."'

Search Results

1. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020

2. Viral hepatitis elimination: Towards a hepatitis-free world

3. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

6. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

7. Advancing the global public health agenda for NAFLD: a consensus statement

8. OC.08.1 PROGRAMMED CELL DEATH 1 GENETIC VARIANT AND LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE

9. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

12. Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C

13. SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD

15. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

18. Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease

19. Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort

21. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

23. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

24. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

25. Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life

26. Characteristics of liver cirrhosis in Italy: results from a multicenter national study

27. Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

28. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

29. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

30. Reply to: 'Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients'

31. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

32. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases

33. The aetiology of chronic hepatitis in Italy: results from a multicentre national study

34. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial

35. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

38. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

39. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

40. Needle track seeding following percutaneous procedures for hepatocellular carcinoma

41. EASL Clinical Practice Guidelines: management of chronic hepatitis B

42. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole

43. Reply

44. Reply

45. Retinol-binding protein 4 (RBP4): A new marker of G1 HCV-induced steatosis

46. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

47. Reply

48. Foreword

49. Ribavirin treatment for chronic hepatitis D: a pilot study

50. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

Catalog

Books, media, physical & digital resources